N-(1H-indazol-5-yl)-2-(thiophen-2-yl)acetamide | 574725-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-(1H-indazol-5-yl)-2-(thiophen-2-yl)acetamide
• 英文别名: N-(1H-indazol-5-yl)-2-thiophen-2-ylacetamide
• CAS: 574725-35-2
• 化学式: C₁₃H₁₁N₃OS
• mdl: MFCD04068397
• 分子量: 257.316
• InChiKey: JPRCQFGMNFQDKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  86
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(1H-indazol-5-yl)-2-(thiophen-2-yl)acetamide 在 potassium fluoride 、 四(三苯基膦)钯 、 碘 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-2-(thiophen-2-yl)acetamide
  参考文献：
  名称：

  Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides

  摘要：

  TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50=3.6nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.

  DOI：

  10.1016/j.bmc.2014.06.027
• 作为产物：
  描述：

  2-噻吩乙酰氯 、 5-氨基吲唑 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以57%的产率得到N-(1H-indazol-5-yl)-2-(thiophen-2-yl)acetamide
  参考文献：
  名称：

  [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  [FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER UTILISANT CEUX-CI

  摘要：

  本教学提供了一种由结构式(I)表示的化合物，或其药用可接受的盐。还描述了一种药物组合物及其使用方法。

  公开号：

  WO2011123937A1

文献信息

• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER UTILISANT CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2011123937A1

  公开（公告）日：2011-10-13

  The present teachings provide a compound represented by Strutural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

  本教学提供了一种由结构式(I)表示的化合物，或其药用可接受的盐。还描述了一种药物组合物及其使用方法。
• Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides
  作者：Radoslaw Laufer、Grace Ng、Yong Liu、Narendra Kumar B. Patel、Louise G. Edwards、Yunhui Lang、Sze-Wan Li、Miklos Feher、Don E. Awrey、Genie Leung、Irina Beletskaya、Olga Plotnikova、Jacqueline M. Mason、Richard Hodgson、Xin Wei、Guodong Mao、Xunyi Luo、Ping Huang、Erin Green、Reza Kiarash、Dan Chi-Chia Lin、Marees Harris-Brandts、Fuqiang Ban、Vincent Nadeem、Tak W. Mak、Guohua J. Pan、Wei Qiu、Nickolay Y. Chirgadze、Henry W. Pauls

  DOI：10.1016/j.bmc.2014.06.027

  日期：2014.9

  TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50=3.6nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.